Essential Premium

Affinity, Janus Henderson Outpace Biopharma Peers in Tough Month

As most life sciences hedge funds lost money in July, Affinity Healthcare and Janus Henderson Biotech gained roughly 8 percent and 4 percent, respectively, extending their gains for 2026.

Continuation Vehicles Ease Pressure on Managers, But LPs Question the Tradeoff

Some allocators say the structures shift costs and risks onto investors seeking liquidity.

Sponsored

A New Cycle Emerges

Why Greenlight Is Betting on These Five Stocks

In his second-quarter letter, David Einhorn outlines the case for new investments, including Comcast and PayPal.

Related Content

A Quick Windfall for Hedge Funds, Another Blow for a Biotech Company’s Early Backers

Stephen Taub

The Rich List: Institutional Investor’s 25th Annual Ranking of the Highest-Earning Hedge Fund Managers

Stephen Taub

AI Meets Biotech — and Hedge Funds Are Buying In

Stephen Taub

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram